IP Library Granted Patent US 11,925,729
Granted Patent B2
US 11,925,729 · App. 17/967,259 · Granted Mar 12, 2024

Drug-coated balloon catheters for body lumens

Inventors: Lixiao Wang (Henderson, NV); Peter Barnett (Shakopee, MN); David Hendrickson (Coon Rapids, MN)
Assignee: Urotronic, Inc.
A61L29/08A61L29/06A61L29/085A61L29/16A61M25/1002A61M25/10185A61M29/02A61B1/307A61L2300/416A61L2300/426A61M2025/105A61M2025/1075A61M2202/0488A61M2205/0205A61M2210/0681A61M2210/1032A61M2210/1039A61M2210/105A61M2210/1053A61M2210/1057A61M2210/106A61M2210/1064A61M2210/1078A61M2210/1085A61M2210/1096A61M2210/166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,925,729
App. No.
17/967,259
Granted
Mar 12, 2024
Kind
B2
Abstract

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Claims (34)

1. A method for treatment of an anastomotic stricture, the method comprising:

providing a balloon catheter such that the balloon catheter is positioned at a target site in a body lumen comprising the anastomotic stricture, the balloon catheter comprising

an elongated balloon, and

a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises an initial drug load of a therapeutic agent;

soaking the balloon catheter in a liquid comprising a soaking media for a soaking period prior to inflation to hydrate the coating layer, wherein the soaking media comprises water, saline solution, or a water solution comprising at least one water-soluble additive;

inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the location of the anastomotic stricture until the balloon achieves an inflated balloon diameter for an inflation period;

deflating the balloon after the inflation period; and

withdrawing the balloon catheter from the body lumen.

2. The method of claim 1 , wherein the soaking comprises soaking the balloon catheter prior to positioning the balloon catheter in the anastomotic stricture.

3. The method of claim 1 , wherein the soaking comprises soaking the balloon catheter after positioning the balloon catheter in the anastomotic stricture.

4. The method of claim 1 , wherein the anastomotic stricture is a non-vascular stricture.

5. The method of claim 1 , wherein exposing the balloon catheter to the liquid comprises holding the balloon catheter in position for the soaking period prior to inflation to hydrate the coating layer.

6. The method of claim 1 , wherein the balloon has thereon a residual drug amount after the withdrawing, wherein the residual drug amount is 70% or less of the initial drug load.

7. The method of claim 1 , wherein the soaking period in combination with the contacting of the coating layer with the stricture is sufficient to release 37% to 97% of the initial drug load.

8. The method of claim 1 , wherein the soaking period comprises at least 1 minute.

9. The method of claim 1 , wherein the balloon catheter comprises an elongated balloon having a main diameter, the elongated balloon comprising at least one neck section, the balloon comprising a first main section and a second main section on opposite sides of the neck section.

10. The method of claim 9 , wherein the at least one neck section comprises an inflated diameter that is smaller than the main diameter when the balloon is inflated, during the inflating the inflated diameter of the neck section is the smallest diameter of the balloon catheter between the first main section and the second main section, during the inflating the inflated diameter of the neck section is greater than a diameter of the neck section prior to the inflation, and the at least one neck section comprises an area of reduced compliance during inflation relative to the first main section and the second main section.

11. The method of claim 9 , wherein the drug coating is on the first main section and the neck.

12. The method of claim 9 , wherein the at least one neck section comprises a reinforcing material around a circumference of the neck section to reduce compliance of the neck section during the inflation.

13. The method of claim 1 , wherein inserting the balloon catheter into the target site in the body lumen comprises inserting the balloon catheter and a scope into the target site in the body lumen.

14. The method of claim 13 , wherein the balloon catheter and the scope are positioned side-by-side or the balloon catheter is loaded into the scope.

15. The method of claim 13 , wherein the balloon catheter and the scope are positioned side-by-side.

16. The method of claim 13 , wherein the balloon catheter is loaded into the scope.

17. The method of claim 13 , further comprising visualizing the balloon catheter with the scope before and/or during the inflating.

18. The method of claim 13 , wherein the scope comprises an endoscope, enteroscope, colonoscope, sigmoidoscope, rectoscope, anoscope, rhinoscope, bronchoscope, or a cystoscope.

19. The method of claim 1 , wherein the therapeutic agent is chosen from paclitaxel, docetaxel, taxol, rapamycin, sirolimus, zotarolimus, everolimus, tacrolimus, mTOR inhibitors, analogues thereof, and combinations thereof.

20. A method for treatment of an anastomotic stricture, the method comprising:

providing a balloon catheter such that the balloon catheter is positioned at a target site in a body lumen comprising the anastomotic stricture, the balloon catheter comprising

an elongated balloon, and

a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises an initial drug load of a therapeutic agent;

soaking and/or flushing the balloon catheter in a liquid comprising a soaking media for a soaking period prior to inflation to hydrate the coating layer, wherein the soaking media comprises water, saline solution, or a water solution comprising at least one water-soluble additive;

inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the location of the anastomotic stricture until the balloon achieves an inflated balloon diameter for an inflation period;

deflating the balloon after the inflation period; and

withdrawing the balloon catheter from the body lumen.

Assignments (4)
SECURITY INTEREST Recorded Jul 23, 2024
From: NOVONATE INC.; PELVALON, INC.; UROTRONIC, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 068057/0959 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: UROTRONIC, INC.
Reel/Frame 066989/0836 →
SECURITY INTEREST Recorded Dec 12, 2023
From: UROTRONIC, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 065839/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2022
From: WANG, LIXIAO; BARNETT, PETER; HENDRICKSON, DAVID
To: UROTRONIC, INC.
Reel/Frame 061442/0405 →
Continuity (13)
Continuation 17133088 · Dec 23, 2020
Continuation In Part 16986683 · Aug 6, 2020
Continuation In Part PCTUS2020019274 · Feb 21, 2020
Division 16135436 · Sep 19, 2018
Continuation In Part PCTUS2018031083 · May 4, 2018
Continuation In Part 15568614
Continuation In Part 14438327
Provisional Application 62859396 · Jun 10, 2019
Provisional Application 62809048 · Feb 22, 2019
Provisional Application 62502212 · May 5, 2017
Provisional Application 62152559 · Apr 24, 2015
Provisional Application 61795790 · Oct 26, 2012
Related Publication 20230050453A1 · Feb 16, 2023
Cited By (4)
US 12,280,179 US 12,280,226 US 12,357,732 US 12,383,710